This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Korea Research Institute of Bioscience and Biotechnology, St Pharm Co., Ltd.. Active years: 2014-2023.
Company Filing History:
1 out of 334 
1 out of 19 
Years Active: 2014-2023
Title: Yejin Jang: Innovator in Nucleoside Derivatives and Cancer Diagnosis
Introduction
Yejin Jang is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the fields of biochemistry and oncology through his innovative research and patented inventions. With a total of 2 patents, Jang's work focuses on the development of novel nucleoside derivatives and methods for cancer diagnosis and treatment.
Latest Patents
Jang's latest patents include groundbreaking inventions that address critical health issues. The first patent pertains to nucleoside or nucleotide derivatives, which are designed for use in pharmaceutical compositions aimed at preventing or treating viral infection-associated diseases. This invention highlights the potential of these derivatives as active ingredients in therapeutic applications.
The second patent introduces a method for the diagnosis and prognosis of cancers using an epigenetic marker. This method specifically utilizes a single CpG site in the TTP (Tristetraprolin) promoter to diagnose liver cancer and regulate its epigenetic status. The invention can also be applied to other cancers and inflammatory diseases characterized by TTP down-regulation and specific methylation patterns.
Career Highlights
Throughout his career, Yejin Jang has worked with notable organizations such as St Pharm Co., Ltd. and the Korea Research Institute of Bioscience and Biotechnology. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to significant advancements in biotechnology.
Collaborations
Jang has collaborated with esteemed colleagues, including Kyungjin Kim and Hwajung Nam. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to impactful research outcomes.
Conclusion
Yejin Jang's contributions to the fields of nucleoside derivatives and cancer diagnosis exemplify the importance of innovation in healthcare. His patents not only advance scientific knowledge but also hold the potential for significant therapeutic applications. Jang's work continues to inspire future research and development in biotechnology.